

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE TO
(Amendment No. 1)

TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR
13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934

Cryoport, Inc.

(Name of Subject Company (Issuer) and Filing Person (Offeror))

WARRANTS TO PURCHASE COMMON STOCK
(Title of Class of Securities)

229050 125

(CUSIP Number of Class of Securities)

Robert Stefanovich
Chief Financial Officer
17305 Daimler Street
Irvine, CA 92614
(949) 470-2300

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications on Behalf of Filing Person)

Copy to:

Anthony Ippolito, Esq.
Snell & Wilmer L.L.P.
600 Anton Boulevard, Suite 1400
Costa Mesa, California 92626
(714) 427-7000

CALCULATION OF FILING FEE:

Transaction valuation ⁽¹⁾	Amount of filing fee ⁽²⁾
\$10,730,000	\$1,335.89

(1) Estimated for purposes of calculating the amount of the filing fee only. The transaction is an offer by the issuer to holders of its \$3.57 original warrants to exchange up to 2,000,000 of such original warrants for an equal number of \$3.00 new warrants of the issuer, conditioned upon the immediate exercise of such new warrants. The transaction valuation is calculated pursuant to Rule 0-11 of the Securities Exchange Act of 1934, as amended. The transaction valuation assumes that 2,000,000 outstanding original warrants are tendered in the offer, and was determined using \$5.365 per original warrant, which represents the average of the high and low sales price of the issuer's original warrants on December 27, 2017, as reported by the NASDAQ Capital Market.

(2) The amount of the filing fee, calculated in accordance with Rule 0-11, equals the transaction valuation multiplied by .0001245.

x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing.

Amount Previously Paid: \$1,335.89

Filing Party: Cryoport, Inc.

Form or Registration Number: 005-85385

Date Filed: January 2, 2018

.. Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

.. third party tender offer subject to Rule 14d-1.

x issuer tender offer subject to Rule 13e-4.

.. going private transaction subject to Rule 13e-3.

.. amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of a tender offer: ..

The alphabetical subsections used in the Item responses below correspond to the alphabetical subsections of the applicable items of Regulation M-A promulgated under the federal securities laws.

If applicable, check the appropriate box(es) below to designate the appropriate note provision(s):

- Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
 - Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)
-
-

INTRODUCTORY STATEMENT

This Amendment No. 1 (this “Amendment No. 1”) amends and supplements the Tender Offer Statement on Schedule TO originally filed by Cryoport, Inc., a Nevada corporation (the “**Company**”), with the Securities and Exchange Commission on January 2, 2018 (the “**Schedule TO**”), pursuant to Rule 13e-4 under the Securities Exchange Act of 1934, as amended (the “**Exchange Act**”), relating to the Company’s offer (the “**Offer**”) to holders of the Company’s outstanding warrants to purchase one share of common stock at an exercise price of \$3.57 per share (the “**Original Warrants**”) to exchange up to 2,000,000 of such Original Warrants for an equal number of warrants to purchase one share of common stock at an exercise price of \$3.00 per share (the “**New Warrants**”), conditioned upon the immediate exercise of such New Warrants.

Pursuant to Rule 12b-15 under the Exchange Act, this Amendment No. 1 amends and supplements only the items of the Schedule TO that are being amended and supplemented hereby, and unaffected items and exhibits in the Schedule TO are not included herein. This Amendment No. 1 should be read in conjunction with the Schedule TO and the related exhibits included therein, as the same may be further amended or supplemented hereafter and filed with the SEC. Capitalized terms herein but not otherwise defined have the meanings set forth in the Schedule TO.

Item 1. SUMMARY TERM SHEET.

The information set forth in Item 4 below is incorporated herein by reference.

Item 4. TERMS OF THE TRANSACTION.

This Amendment No. 1 amends and supplements Items 1 and 4 of the Schedule TO as follows:

The Company added an additional condition to the Offer that the Company shall have concluded that consummation of the Offer will not constitute a “Rule 13e-3 transaction”, as such term is defined in Rule 13e-3 under the Exchange Act. Throughout the Schedule TO, the Offer Letter/Prospectus and the other Offering Materials (as defined in the Offer Letter/Prospectus), all references to the conditions to the Offer are hereby amended to include the condition that the Company shall have concluded that consummation of the Offer will not constitute a “Rule 13e-3 transaction”, as such term is defined in Rule 13e-3 under the Exchange Act.

Item 12. EXHIBITS.

This Amendment No. 1 amends and restates Item 12 of the Schedule TO as follows:

The following are exhibits to this Schedule TO:

- (a) (1)(A) Form of Letter of Transmittal (incorporated by reference to Exhibit 99.1 of the Company's Registration Statement on Form S-4 filed on January 2, 2018).
 - (1)(B) Form of Notice of Guaranteed Delivery (incorporated by reference to Exhibit 99.2 of the Company's Registration Statement on Form S-4 filed on January 2, 2018).
 - (1)(C) Form of Letter to Warrantholders of Record (incorporated by reference to Exhibit 99.3 of the Company's Registration Statement on Form S-4 filed on January 2, 2018).
 - (1)(D) Form of Letter to Brokers and Other Nominee Holders (incorporated by reference to Exhibit 99.4 of the Company's Registration Statement on Form S-4 filed on January 2, 2018).
 - (1)(E) Form of Letter to Clients of Brokers and other Nominee Holders (incorporated by reference to Exhibit 99.5 of the Company's Registration Statement on Form S-4 filed on January 2, 2018).
 - (1)(F) Letter to Original Warrant Holders, dated January 22, 2018.
 - (4)(A) Offer Letter/Prospectus, dated January 2, 2018 (incorporated by reference to the Company's Registration Statement on Form S-4 filed on January 2, 2018).
 - (5)(A) Form of New Warrants issued in connection with the Offer (incorporated by reference to Annex A of the Company's Registration Statement on Form S-4 filed on January 2, 2018).
 - (b) Not applicable.
 - (d) (1) Letter Agreement, dated January 2, 2018, by and between the Company and Jerrell W. Shelton.*
 - (2) Letter Agreement, dated January 2, 2018, by and between the Company and Dr. Robert Hariri.*
 - (3) Form of Warrant Agreement relating to the Original Warrants (including the Form of Original Warrant certificate issued in connection with public offering of Units), by and between the Company and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.28 of the Company's Amendment No. 4 to Registration Statement on Form S-1 filed on June 22, 2015).
 - (g) None.
 - (h) Legal Opinion of Snell & Wilmer L.L.P. as to certain tax matters (incorporated by reference to Exhibit 8.1 of the Company's Registration Statement on Form S-4 filed on January 2, 2018).
-

SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

CRYOPORT, INC.

By: /s/ Robert Stefanovich

Name: Robert Stefanovich

Title: Chief Financial Officer

Date: January 22, 2018

[Cryoport Letterhead]

January 22, 2018

To the Holders of Original Warrants:

This letter is being distributed by Cryoport, Inc., a Nevada corporation (the “**Company**”), to holders of the Company’s outstanding warrants to purchase shares of common stock at an exercise price of \$3.57 per share (the “**Original Warrants**”) in connection with the Company’s offer (the “**Offer**”) to such holders to exchange up to 2,000,000 of such Original Warrants for (1) an equal number of warrants to purchase one share of common stock at an exercise price of \$3.00 per share (the “**New Warrants**”), conditioned upon the immediate exercise of such New Warrants.

This letter serves as a reminder that the Offer expires at 5:00 p.m., Eastern Time on February 2, 2018, unless extended by the Company in its sole discretion (the “**Expiration Date**”) and notice that the Company amended and restated the offer letter/prospectus relating to the Offer (as it may be amended and/or supplemented from time to time, the “**Offer Letter/Prospectus**”) in the Amendment No. 1 to the Registration Statement on Form S-4 filed by the Company with the Securities and Exchange Commission on January 22, 2018. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the Offer Letter/Prospectus.

The Offer Letter/Prospectus includes revised terms and conditions and information that were not previously included in the offer letter/prospectus, dated January 2, 2018, which was previously distributed by the Company to you. Such changes include, without limitation, a condition to the Offer that the Company shall have concluded that consummation of the Offer will not constitute a “Rule 13e-3 transaction”, as such term is defined in Rule 13e-3 under the Exchange Act. The Offer would constitute a Rule 13e-3 transaction if the Offer was reasonably likely to result in the Public Original Warrants being delisted from the NASDAQ Capital Market or deregistered under the Securities Exchange Act of 1934, as amended. You should carefully read the Offer Letter/Prospectus, together with any related documents the Company provides to you, before making a decision to participate in the Offer.

If you elect to tender Original Warrants in response to the Offer, please follow the instructions in the Offer Letter/Prospectus and the related documents, including the Letter of Transmittal previously distributed by the Company. The Letter of Transmittal, certificate(s) representing the Original Warrants, and payment of the exercise price of the New Warrants must be delivered to Continental Stock Transfer & Trust Company, the depository for the Offer, on or before the Expiration Date.

If you have already tendered Original Warrants and now do not desire to participate in the offer, you may withdraw your tender by following the instructions in the Offer Letter/Prospectus before the Expiration Date.

Please direct questions or requests for assistance regarding the Offer and the Offering Materials to the Company at:

Cryoport, Inc.
17305 Daimler Street,
Irvine, CA 92614
Attn: Robert Stefanovich, Chief Financial Officer, Telephone: (949) 681-2727
or
Thomas J. Heinzen, VP, Corporate Development and Investor Relations, Telephone: (949) 681-2723
(email: ir@cryoport.com)

Very truly yours,

Cryoport, Inc